Why the study?
Is gemfibrozil cost-effective for preventing major cardiovascular events in male coronary heart disease patients with low HDL-C and low LDL-C?
Population
Male coronary heart disease patients with low levels of HDL-C and low levels of LDL-C
Design
Other
Follow-up
simulated lifetime
Authors
Loading...
Supports VA formulary inclusion for cost savings; leaves open broader adoption at commercial prices.
Is gemfibrozil cost-effective for preventing major cardiovascular events in male coronary heart disease patients with low HDL-C and low LDL-C?
Gemfibrozil is highly cost-effective, and potentially cost-saving at VA prices, for reducing major cardiovascular events in men with coronary heart disease and low HDL-C/LDL-C.
John A. Nyman (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: